All News

New once-daily oral GLP‑1 agonist cuts hemoglobin A1c and drives 5% to 10% weight loss—with no fasting rules—expanding options for obesity and diabetes care.

Three psychiatric pharmacists highlight trends in psychiatric pharmacotherapy that were shared at the AAPP 2026 Annual Meeting.

OTC GLP-1 boosters are marketed for weight loss, but pharmacists should help patients distinguish evidence-based care from supplement claims.

Emerging data are supporting less intensive antithrombotic strategies for LVADs that could reduce bleeding complications without compromising thromboembolic protection.

The findings emphasize the growing role of precision oncology and integrated EHR infrastructure in expanding access to targeted therapies.

Pharmacists push antimicrobial stewardship into clinics and long-term care, tackling antifungal resistance, rapid diagnostics, vaccines, and public health leadership.

TrumpRx lists 600+ generic drugs with live cash prices, helping patients beat co-pays and sidestep PBMs amid rising drug prices.

Empowered pharmacy technicians strengthen adherence and support safer, smoother patient care.

A large analysis found that measurable declines in processing speed, global cognition, and executive function began up to 8 years before a cardiovascular event.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses how continuous glucose monitoring (CGM) technology and automated insulin delivery systems are transforming pharmacists’ roles.

Pharmacy Times interviews Helen Latimer, MPH, about new real-world data examining racial disparities and evolving trends in HRR genetic testing among patients with metastatic prostate cancer and the implications for equitable access to precision oncology care.

Natalie Bellini, DNP, FNP-BC, BC-ADM, explains why continuous glucose monitor (CGM) persistence so often breaks down after initiation and how pharmacists can intervene at the point of dispensing.

Kunz Coyne expresses interest in antimicrobial stewardship discussions at the joint MAD-ID/SIDP meeting as clinicians continue refining their role in practice.

The FDA approved baxdrostat based on meaningfully positive results from the phase 3 BaxHTN trial.

The FDA approved 2 new indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer, expanding its use in both neoadjuvant and adjuvant settings.

Minimizing sedation, cognitive impairment, and addiction risk are key priorities.

Rapid insulin discontinuation occurred with tirzepatide 2.5 mg weekly in long-standing type 2 diabetes, demonstrating a low-dose responder phenotype and pharmacist-led CGM-guided deprescribing.

FDA approval clears interchangeable golimumab biosimilars for rheumatoid arthritis and ulcerative colitis, promising lower-cost TNF therapy.

As pharmacies expand into offering immunizations and other clinical services, the rules for the Part B medical side have moved away from the traditional pharmacy side.

Six-year follow-up data from the SEQUOIA trial showed that zanubrutinib provided durable PFS and strong long-term outcomes in treatment-naïve CLL/SLL.

Pharmacists lead antifungal and antibiotic stewardship beyond hospitals, using rapid diagnostics, vaccines, and equity to curb resistance.

Pharmacists must balance the lifesaving automation of advanced technology with the harsh reality of a high-cost, high-risk transition.

Pharmacists can counter misinformation on SSRIs with evidence-based antidepressant guidance, safe tapering advice, and patient-centered depression care.

Pharmacy technicians are vital to obesity care, improving access, adherence, and patient engagement in increasingly complex treatment pathways.

A landscape overview of enfortumab vedotin’s expanding role across bladder cancer settings—from MIBC to earlier lines of therapy—with a focus on pharmacist-led patient support, AE management, and real-world implementation.

Darren Triller, PharmD, walks through the relative ease and impact of each of the 5 ADAPT priority areas, makes the case for dashboard-driven population health management.

Efficacy and safety were evaluated in the phase 3 IMvigor011 trial.

Clinical pharmacists Andrew Willeford and Laura Velazquez explore the paradigm shift in oHCM management, highlighting best practices for pharmacist-led clinical workflows in health-system practice.